Keratoconus in the U.S. was classically a “wait and see” corneal disease.
Though improvements in vision could be obtained, traditionally with rigid gas permeable lenses, we as practitioners could do nothing to intervene and stop the progressive nature of the disease.
On a yearly basis, we would monitor our patients with keratoconus and watch keratoconic changes hoping “this will be the year we will see stability and the end of the progressive lifecycle”. We watched these keratoconic corneas progressively thin, steepen and scar as our patient’s vision, and more importantly, quality of life deteriorated.
If you would like to read this complete article, please signup to become a member.
You do not have access to this post.
